ArticleJournal of neurology2026
Extensive dysautonomia in early-stage multiple system atrophy reflects survival differences: insights from data-driven subtypes.
Article in Journal of neurology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionMultiple system atrophy (MSA) is a clinically heterogeneous disorder. Conventional motor phenotype-based classification provides limited prognostic information. Previously, we identified data-driven subtypes of early-stage MSA using a latent class analysis (LCA) that incorporated both motor and non-motor features. However, the prognostic significance of these subtypes remains unclear.
methodsWe analyzed the survival outcomes in a previously reported cohort of 61 patients with probable or possible MSA enrolled within three years of motor symptom onset. Patients were classified according to LCA-derived subtypes and dichotomized into an extensive or restricted dysautonomia group based on shared autonomic profiles. Overall survival was assessed using Kaplan-Meier analysis and compared using the log-rank test. Cox proportional hazards models were used to estimate hazard ratios (HRs) with progressive adjustments for the age at onset, sex, baseline disease severity (Unified Multiple System Atrophy Rating Scale, UMSARS Part I), and disease duration at enrollment.
resultsSurvival analysis was performed in 60 patients, 47 of whom died by the end of follow-up. The extensive dysautonomia group showed a significantly shorter median survival than the restricted group (6.0 vs. 7.0 years; log-rank p = 0.008). After adjusting for the age at onset and sex, the restricted group had a lower risk of mortality (adjusted HR: 0.538, 95% CI 0.290-0.996; p = 0.049). This association was attenuated after additional adjustments for the baseline disease severity (UMSARS Part I) and disease duration.
conclusionsData-driven subtypes defined by early symptom patterns correspond to clinically meaningful survival differences in patients with MSA. Extensive dysautonomia reflects a more malignant, globally severe phenotype than isolated autonomic involvement, highlighting the prognostic relevance of incorporating non-motor features into early MSA classification.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.